Teacher Retirement System of Texas Boosts Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Teacher Retirement System of Texas raised its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 27.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,383 shares of the company's stock after buying an additional 1,369 shares during the quarter. Teacher Retirement System of Texas' holdings in Krystal Biotech were worth $1,000,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in Krystal Biotech in the 3rd quarter worth about $40,000. Avanza Fonder AB bought a new position in Krystal Biotech during the fourth quarter worth about $119,000. KBC Group NV increased its stake in shares of Krystal Biotech by 46.3% in the fourth quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after purchasing an additional 297 shares in the last quarter. Blue Trust Inc. raised its position in shares of Krystal Biotech by 74.4% in the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares during the period. Finally, US Bancorp DE lifted its stake in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Performance

Krystal Biotech stock traded up $6.42 during midday trading on Wednesday, hitting $181.00. 235,736 shares of the company's stock were exchanged, compared to its average volume of 289,578. The company has a market cap of $5.21 billion, a P/E ratio of 60.54 and a beta of 0.87. The stock has a 50-day moving average price of $172.47 and a two-hundred day moving average price of $173.31. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company's revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter last year, the company posted $0.30 EPS. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target for the company. Chardan Capital boosted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. HC Wainwright restated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Finally, Citigroup lifted their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $220.00.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).